Jan 28, 2019
Kanazawa University Research: Scientists Successfully Obtain Synthetic Growth Factor Compatible to the Native Protein
Oct 29, 2018
Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® AR-V7 Nucleus Detect(TM) Test in Patients with Metastatic Castrate Resistant Prostate Cancer Effective December 10
Oct 23, 2018
New Kind of Compound Shows Early Promise against Prostate Cancer
Jun 28, 2018
Blood Test Predicts Treatment Response and Survival for Patients with Metastatic Prostate Cancer
May 16, 2018
Epic Sciences and Its Collaborators to Present New Data at ASCO 2018
May 10, 2018
Essa Pharma Inc. Regains Compliance with NASDAQ Listing Requirements
Mar 30, 2018
Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect(TM) Test in Patients with Metastatic Castration-Resistant Prostate Cancer
Feb 26, 2018
Genomic Health Expands Offering to Prostate Cancer Patients with Launch of Oncotype DX® AR-V7 Nucleus Detect(TM) Test to Predict Treatment Response in Metastatic Disease
Feb 09, 2018
Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC® ARV-110 at ASCO 2018 Genitourinary Cancers Symposium
Nov 15, 2017
Oncotarget: Researchers identify potential therapeutic target in aggressive breast cancer cells
Nov 02, 2017
Arvinas Nominates Oral Clinical Candidate for Androgen Receptor Degrader Program
Oct 13, 2017
Liquid Biopsy Test Identifies Androgen Receptor Protein Expression in Circulating Tumor Cells in Women with Metastatic Breast Cancer
Sep 25, 2017
M.D. Science Lab Launches BioXgenic 12 Hour X-Treme Testosterone Booster With Unique Prostate Protection Advancement
Sep 05, 2017
TransMedia Group to Boost Awareness of T Genix, America's Top Testosterone Booster